Latest articles
No of your stocks has realtime/relevant news articles that can be accessed.
Take a look into our News feed to read about recent price changes and analysis.
Sentiment statistics ?
Financial Histories
Please use our Financial history templates to chart, read and compare all 10'Q filings in depth.
Overview
RXDXDay performance
| RXDX | |
|---|---|
| Price | 199.92 |
| Change Pct | 0.09 |
| Change Abs | 0.18 |
| Market Cap | 9.6 billion |
| Eps | -3.54 |
| Pe Ratio | -56.47 |
| Outstanding Shares | 47.8 million |
| Volume | 1.8 million |
| Avg Volume | 1.2 million |
| Industry | Biotechnology |
| Sector Name | Health Care |
| Country Short Name | US |
| Announcement Earnings | 2021-05-13 20:00:00+00:00 |
Dividends
There is no dividend data to display. Refer our Dividend calendar for other accurate data.
Risk Profiles
Please sign up and become a member to view all risk profiles.
Peers
BPMC
MDGL
KRYS
3 Login now
4 Login now
5 Login now
6 Login now
7 Login now
8 Login now
9 Login now
Focus
Use our 'Focus' approach as text-and chart based summaries of the financial standing for a company. They are solely focussing on the company's market, risks and chances.
RXDX
Company descriptions
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD;